Enliven Therapeutics ELVN Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's deferred tax assets and other non-current assets?
- Enliven Therapeutics (ELVN) reported deferred tax assets and other non-current assets of $1.19M in Q1 2026.
- How has Enliven Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- Enliven Therapeutics's deferred tax assets and other non-current assets decreased by 83.5% year-over-year, from $7.2M to $1.19M.
- What is the long-term trend for Enliven Therapeutics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Enliven Therapeutics's deferred tax assets and other non-current assets has grown at a 49.4% compound annual growth rate (CAGR), from $88K to $656K.